MENU
HUM
Stock ticker: NYSE
PRICE
CHANGE
CAPITALIZATION

HUM stock forecast, quote, news & analysis

Humana is one of the largest private health insurers in the US, and the firm has built a niche specializing in government-sponsored programs, with nearly all its medical membership stemming from Medicare, Medicaid, and the military's Tricare program... Show more

A.I.Advisor
published price charts
A.I.Advisor
Nov 02, 2026

Humana (HUM) Stock Analysis: Medicare Advantage Star Ratings Fuel a Rebound

Key Takeaways

  • Humana (HUM) shares rose roughly 6.7% over the trailing 30 days, closing near $414 in late October 2026.
  • The advance followed a sharp improvement in 2027 Medicare Advantage Star Ratings, with 95% of members enrolled in plans rated four stars or higher.
  • The stock touched a 52-week high near $456 shortly after the ratings announcement before consolidating.
  • Management reaffirmed fiscal 2026 adjusted EPS guidance of at least $9.00 per share.
  • Several firms upgraded the stock in October, including Cantor Fitzgerald, Raymond James, Baird, and Oppenheimer.
  • Third-quarter 2026 results are scheduled for release on November 6, 2026.
  • For additional detail, explore Humana's Price Targets, Earnings, and Forecast pages.
  • Investors can also browse Trending AI Robots for automated trading ideas across the market.

Current Market Snapshot

Humana shares have spent the trailing month rebuilding toward multi-month highs after a volatile stretch. The stock moved from the high-$380 range in early October to a close near $414 by late October, gaining roughly 6.7% over that span. The standout session came on October 9, when Humana surged to a 52-week high near $456 on heavy volume following its Medicare Advantage Star Ratings announcement, before settling back into the low-$410 to mid-$420 range.

The rebound reflects a broader re-rating across the managed-care sector. A larger-than-expected 2.48% Medicare Advantage payment increase for 2027, finalized earlier in the year, eased regulatory fears that had pressured insurers, and Humana's improved quality scores added a company-specific catalyst. Sentiment has turned more constructive, though the stock remains well below the elevated valuation multiples it carried in prior years.

Humana (HUM) Business Overview and Competitive Position

Humana Inc. is one of the largest health insurance companies in the United States and a leading provider of Medicare Advantage, the privately administered version of the federal Medicare program. Headquartered in Louisville, Kentucky, the company derives the majority of its revenue from government-sponsored plans, including Medicare Advantage, Medicare prescription drug plans, and Medicaid contracts.

Beyond its insurance segment, Humana operates CenterWell, a healthcare services platform spanning primary care, home health, and pharmacy solutions. This vertically integrated model is central to the company's strategy of coordinating care, managing medical costs, and improving clinical outcomes for aging populations. Investors follow Humana closely because Medicare Advantage is its dominant profit driver, making the stock highly sensitive to government payment rates, Star Ratings, medical-cost trends, and regulatory changes.

Recent Developments Driving HUM

The defining event of the period was the October 9 announcement that 95% of Humana's Medicare Advantage members are enrolled in 2027 plans rated four stars or higher by the Centers for Medicare and Medicaid Services, up sharply from the prior year and well above analyst expectations. Four-star and higher plans qualify for quality-bonus payments, strengthening Humana's 2028 revenue outlook. The company also reaffirmed its fiscal 2026 adjusted EPS guidance of at least $9.00.

In mid-October, Humana announced that CenterWell will replace its existing joint ventures with funds affiliated with Welsh, Carson, Anderson & Stowe with a new arrangement involving HPS Investment Partners, a subsidiary of BlackRock, to manage senior primary-care clinics. The company said the new structure reduces balance-sheet liabilities and lowers its cost of capital.

Additional developments included the declaration of a $0.885-per-share quarterly dividend in late October, an expanded 2027 Medicare Advantage product lineup with $0 or low-premium plans across roughly 2,600 counties, and a wave of analyst upgrades, with price targets ranging from $460 to $596. Humana, a more Medicare-concentrated operator than rivals such as UnitedHealth Group (UNH) and CVS Health (CVS), remains especially leveraged to this program's funding and quality dynamics.

Trending AI Robots

Tickeron's Trending AI Robots page showcases a curated selection of the platform's AI-driven trading bots. While Tickeron offers hundreds of bots that trade thousands of tickers, only the top-performing and most relevant strategies are featured in this section. The bots vary widely in trading approach, timeframe, and performance metrics, allowing users to compare strategies that align with different risk tolerances and market conditions. The page is designed to help traders and investors quickly identify automated strategies that are currently generating attention. Those interested in systematic approaches can explore the section to see which bots are standing out at any given time.

2026 Outlook and What Investors Should Watch

The near-term focus is Humana's third-quarter 2026 earnings release on November 6, which will shed light on medical-cost trends, membership retention, and progress toward its margin-recovery targets. Management has set a goal of returning individual Medicare Advantage pretax margins to at least 3% by 2028, and the improved Star Ratings are a key building block for that plan, since bonus payments tied to the higher scores do not arrive until 2028.

Investors should also monitor the 2027 Medicare Advantage bid cycle, benefit adjustments, and competitive enrollment trends during the fall open-enrollment period. Regulatory developments, including future payment-rate notices and oversight of risk-adjustment practices, remain important swing factors for the entire managed-care sector. Execution on medical-cost control and the CenterWell integration will ultimately determine whether the recent re-rating is sustained.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

A.I.Advisor
a Summary for HUM with price predictions
Nov 20, 2026

HUM's RSI Indicator recovers from overbought zone

The 10-day RSI Oscillator for HUM moved out of overbought territory on November 17, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 32 instances where the indicator moved out of the overbought zone. In 21 of the 32 cases the stock moved lower in the days that followed. This puts the odds of a move down at 66%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on November 18, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on HUM as a result. In 47 of 77 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 61%.

The Moving Average Convergence Divergence Histogram (MACD) for HUM turned negative on November 18, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 30 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 61%.

HUM moved below its 50-day moving average on November 18, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HUM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 64%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

Following a +3.96% 3-day Advance, the price is estimated to grow further. Considering data from situations where HUM advanced for three days, in 224 of 350 cases, the price rose further within the following month. The odds of a continued upward trend are 64%.

HUM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. HUM’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 83 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.711) is normal, around the industry mean (3.520). P/E Ratio (40.612) is within average values for comparable stocks, (126.353). HUM's Projected Growth (PEG Ratio) (1.304) is slightly higher than the industry average of (0.786). Dividend Yield (0.008) settles around the average of (0.009) among similar stocks. P/S Ratio (0.319) is also within normal values, averaging (0.569).

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HUM’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

A.I.Advisor
published Dividends

HUM is expected to pay dividends on November 27, 2026

Humana HUM Stock Dividends
A quarterly dividend of $0.88 per share will be paid with a record date of November 27, 2026, and an ex-dividend date of October 30, 2026. The last dividend of $0.88 was paid on July 31. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Unitedhealth Group (NYSE:UNH), CVS HEALTH Corp (NYSE:CVS), Elevance Health (NYSE:ELV), Cigna Group (The) (NYSE:CI), Humana (NYSE:HUM), Centene Corp (NYSE:CNC).

Industry description

Managed healthcare industry focuses on providing health/medical and disability insurance plans, generally intended to reduce the cost of for-profit health care. The insurance products might be provided through employer-paid (fully or partly) insurance and benefit programs, or through Medicare/Medicaid. Some of the largest providers of managed health care include Aetna, Humana Inc., and Cigna, and UnitedHealthcare.

Market Cap

The average market capitalization across the Managed Health Care Industry is 67.69B. The market cap for tickers in the group ranges from 335.99K to 353.79B. UNH holds the highest valuation in this group at 353.79B. The lowest valued company is IHGP at 335.99K.

High and low price notable news

The average weekly price growth across all stocks in the Managed Health Care Industry was -12%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was 1%. PGNY experienced the highest price growth at -1%, while CLOV experienced the biggest fall at -25%.

Volume

The average weekly volume growth across all stocks in the Managed Health Care Industry was 80%. For the same stocks of the Industry, the average monthly volume growth was 91% and the average quarterly volume growth was 67%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 61
P/E Growth Rating: 44
Price Growth Rating: 54
SMR Rating: 72
Profit Risk Rating: 91
Seasonality Score: -6 (-100 ... +100)
Humana (HUM) Stock Analysis: Medicare Advantage Star Ratings Fuel a Rebound